CHRS vs. CGEN, BDTX, CCCC, TVTX, FDMT, NUVB, ABUS, SRRK, ZYME, and ARCT
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Compugen (CGEN), Black Diamond Therapeutics (BDTX), C4 Therapeutics (CCCC), Travere Therapeutics (TVTX), 4D Molecular Therapeutics (FDMT), Nuvation Bio (NUVB), Arbutus Biopharma (ABUS), Scholar Rock (SRRK), Zymeworks (ZYME), and Arcturus Therapeutics (ARCT). These companies are all part of the "medical" sector.
Compugen (NASDAQ:CGEN) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
Compugen has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Compugen has higher earnings, but lower revenue than Coherus BioSciences. Compugen is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
Coherus BioSciences received 132 more outperform votes than Compugen when rated by MarketBeat users. Likewise, 65.13% of users gave Coherus BioSciences an outperform vote while only 64.36% of users gave Compugen an outperform vote.
In the previous week, Coherus BioSciences had 1 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Coherus BioSciences and 3 mentions for Compugen. Coherus BioSciences' average media sentiment score of 0.63 beat Compugen's score of 0.56 indicating that Compugen is being referred to more favorably in the media.
Compugen has a net margin of 0.00% compared to Compugen's net margin of -19.64%. Compugen's return on equity of 0.00% beat Coherus BioSciences' return on equity.
12.2% of Compugen shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Compugen presently has a consensus price target of $4.00, suggesting a potential upside of 125.99%. Coherus BioSciences has a consensus price target of $8.00, suggesting a potential upside of 365.12%. Given Compugen's higher probable upside, analysts plainly believe Coherus BioSciences is more favorable than Compugen.
Summary
Coherus BioSciences beats Compugen on 9 of the 17 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
